Results 81 to 90 of about 1,853,915 (311)
JAMA Oncology, 2020 Key Points Question Does adding ipilimumab to nivolumab improve clinical outcomes for patients with advanced hepatocellular carcinoma previously treated with sorafenib?
T. Yau +20 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Chronic TGF‐β exposure drives epithelial HCC cells from a senescent state to a TGF‐β resistant mesenchymal phenotype. This transition is characterized by the loss of Smad3‐mediated signaling, escape from senescence, enhanced invasiveness and metastatic potential, and upregulation of key resistance modulators such as MARK1 and GRM8, ultimately promoting
Minenur Kalyoncu +11 more
wiley +1 more source
Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients. A multicentre cohort study [PDF]
, 2018 The role of pathological findings after locoregional treatments as predictors of hepatocellular cancer recurrence after liver transplantation has been poorly addressed.
Angelico, Mario +17 more
core +1 more source
Scientific ReportsHepatocellular carcinoma (HCC) is known for its high invasiveness, high fatality rate. Both hypoxia and senescence play crucial roles in the initiation and progression of cancer, yet their prognostic implications in HCC are yet to be fully understood ...
Fuqing Chen +7 more
doaj +1 more source
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
New England Journal of Medicine, 2018 BACKGROUND Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the ...
G. Abou-Alfa +21 more
semanticscholar +1 more source
Signal Transduction and Targeted Therapy, 2020 Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately,
Weiwei Tang +11 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau +11 more
wiley +1 more source
Focal adhesion kinase: Insight into molecular roles and functions in hepatocellular carcinoma [PDF]
, 2017 Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Due to the high incidence of post-operative recurrence after current treatments, the identification of new and more effective drugs is required.
Alisi, Anna +4 more
core +2 more sources
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Liver Cancer, 2020 Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people.
Jian Zhou +77 more
semanticscholar +1 more source
Interplay of integrins and selectins in metastasis
Molecular Oncology, EarlyView.Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva +2 more
wiley +1 more source